RVX Share Price

Open 1.71 Change Price %
High 1.75 1 Day -0.01 -0.58
Low 1.68 1 Week 0.00 0.00
Close 1.70 1 Month -0.09 -5.03
Volume 12732 1 Year 0.18 11.84
52 Week High 2.47
52 Week Low 1.10
RVX Important Levels
Resistance 2 1.76
Resistance 1 1.74
Pivot 1.71
Support 1 1.66
Support 2 1.64
TSE Canada Most Active Stocks
BIN 41.40 -1.62%
BIN 41.40 -1.62%
LSG 2.08 8.33%
LSG 2.08 8.33%
LSG 2.08 8.33%
BBD-B 2.74 4.58%
TBE 0.03 0.00%
K 4.71 5.37%
K 4.71 5.37%
BTO 3.76 2.17%
More..
TSE Canada Top Gainers Stocks
CUR 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
ST 0.02 100.00%
ST 0.02 100.00%
TVI 0.02 100.00%
MM 0.08 14.29%
MM 0.08 14.29%
CUM 0.90 13.92%
CUM 0.90 13.92%
More..
TSE Canada Top Losers Stocks
GBV 0.46 -24.59%
IMP 0.07 -12.50%
IMP 0.07 -12.50%
IMP 0.07 -12.50%
GTX 3.59 -10.47%
GTX 3.59 -10.47%
CTU-A 0.19 -9.52%
CCZ 0.13 -7.14%
GGA 0.14 -6.67%
DEJ 0.14 -6.67%
More..

Resverlogix Corp (TSE: RVX)

RVX Technical Analysis 2
As on 17th Jan 2017 RVX Share Price closed @ 1.70 and we RECOMMEND Buy for LONG-TERM with Stoploss of 1.49 & Strong Sell for SHORT-TERM with Stoploss of 1.76 we also expect STOCK to react on Following IMPORTANT LEVELS.
RVX Target for January
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
RVX Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.resverlogix.com
RVX Address
RVX
279 Midpark Way S.E.
Suite 202
Calgary, AB T2X 1M2
Canada
Phone: 403-254-9252
Fax: 403-256-8495
RVX Latest News
Resverlogix Announces Presentation at 9th Annual Biotech Showcase Conference ...   Canada NewsWire (press release)   - 06th Jan 17
The Life Sciences Report Examines Resverlogix's New Trial   Marketwired (press release)   - 04th Aug 16
Epigenetics: Cancer and Beyond   The New York Academy of Sciences   - 08th Jul 16
Zenith lands dough for bro, moves its lead cancer program into the clinic   BioWorld Online   - 18th May 16
Resverlogix Commences Phase 3 Clinical Trial BETonMACE With Apabetalone   PR Newswire (press release)   - 26th Oct 15
Resverlogix in Discussions to Be Bought, CEO Says   Bloomberg   - 28th Apr 15
Resverlogix: Analysis Of The Science Behind RVX-208   Seeking Alpha   - 08th Apr 15
Resverlogix Closes $1.6 million Private Placement   Canada NewsWire (press release)   - 15th Aug 13
Resverlogix ASSERT Trial Data Illustrates Potential for RVX-208 in Alzheimer's ...   PR Newswire (press release)   - 25th Jan 11
Arthur J. Higgins, CEO of Bayer HealthCare, Appointed to Resverlogix Board of ...   PR Newswire (press release)   - 01st Feb 10
Interactive Technical Analysis Chart Resverlogix Corp ( RVX TSE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Resverlogix Corp
RVX Business Profile
Resverlogix Corp., a clinical stage cardiovascular company, develops compounds, which include a therapeutic increase in Apolipoprotein A-I. It primarily develops RVX-208, a small molecule that has completed a Phase IIb clinical trial SUSTAIN and is undergoing a second Phase IIb trial ASSURE for the treatment of atherosclerosis and other chronic diseases, such as neurodegenerative disorders, diabetes mellitus, and Alzheimer's disease. The company is headquartered in Calgary, Canada.